Daxor - DXR Forward P/S Multiple

Corporate company logo of daxor.com (DXR)

The investment potential of Daxor Corporation (DXR) is based on the production of critical blood analysis systems for hospitals. The forward P/S metric visualizes the market valuation of the asset, where the value of 327.20 characterizes this level. Stability is ensured by a conservative approach to capital and asset transparency, as well as the high reputation of management, which is integrating diagnostics into medical standards.

Daxor - DXR Forward Price-to-Revenue Multiple (period 07/04/2022 - 11/14/2026)

Daxor Corp. (DXR) - metric breakdowns and financial figures

- current price and projected stock value:
Stock Price daxor.com|DXR - Broker Consensus Forecast
- issuer market value details:
Market Capitalization Daxor Corp.|DXR - Company Buyout Price
- issuer book value statistics:
Book Value per Share Daxor|DXR - Company Net Assets|Market Capitalization to Book Value Ratio daxor.com|DXR - Company Total Assets
- company liabilities and liquidity data:
Debt to Equity Daxor Corporation|DXR - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Daxor Corporation|DXR - Aggregate Debt Obligations|Debts to Book Capitalization Daxor Corporation|DXR - Long-Term Debt|Company Short-Term Debt Daxor|Quick Liquidity Indicator daxor.com
- financial results and valuation multiples details:
DXR - Net Profit|Projected Future Earnings Daxor Corporation|DXR - Business Payback Period|Future Price to Earnings Daxor Corp|DXR - Market Cap to Earnings and Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Daxor Corp|DXR - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Daxor|DXR - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months daxor.com|DXR - Earnings per share growth this year|Expected earnings per share growth for next year Daxor Corporation
- sales and revenue data:
DXR - Company Total Sales|Projected Sales Volume daxor.com|DXR - Market Cap to Revenue Ratio|Forward P/S Multiple Daxor
Summary company analysis:Daxor Corp. DXR
Original product of Daxor Corp

The forward P/S reflects the ratio of the current market value of Daxor Corporation (DXR) to its projected revenue for the coming year, measuring the extent of growth expectations currently priced in. By analyzing the business's forward P/S, an investor assesses the risk of overpayment, which in this instance is mitigated by its status as the gold standard of cardiology precision and the exceptional stability of demand for blood volume measurement systems.

Competitor analysis

Forward P/S Multiple ABT (Abbott Laboratories)|TMO: Market Cap to Projected Revenue|GE HealthCare Technologies - Forward P/S Multiple|Market Cap to Expected Sales Ratio Mettler-Toledo International MTD|WAT: Forward P/S Multiple|TECH - Market Cap to Expected Sales Ratio|BRKR (Bruker BioSpin) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Azenta Life Sciences (AZTA)|Forward P/S Multiple VREX|Forward P/S Multiple semlerscientific.com (SMLR)|Price-to-Projected Revenue Ratio Butterfly Network BFLY|Mesa Labs Corp - Price-to-Projected Revenue Ratio|quantum-si.com - Forward P/S Multiple|Forward Price to Sales NNOX (Nanox)|QTRX: Forward P/S Multiple|Market Cap to Future Revenue Ratio 908devices.com (MASS)|CV (CapsoVision) - Forward P/S Multiple|MXCT - Projected Price to Revenue|Forward Price-to-Revenue Multiple RPID (rapidmicrobio.com)|Forward P/S Multiple Seer Inc. (SEER)|Forward P/S Multiple HYPR (hyperfine.io)|Market Cap to Expected Sales Ratio fonar.com (FONR)|MDAI - Price-to-Projected Revenue Ratio|Future Price to Revenue VIVS|Aclarion Corporation (ACON) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple Akoya Biosciences Inc|THMO (ThermoGenesis Holdings, Inc.) - Forward P/S Multiple|Market Cap to Future Revenue Ratio talis.bio TLIS|Price-to-Projected Revenue Ratio T2 Biosystems, Inc (TTOO)